Abstract
Purpose: The study was conducted to study the effect of low dose of Mitomycin-C (0.2 mg/ml) as an adjunct for nasolacrimal duct probing to treat adults with primary acquired nasolacrimal duct obstruction and to study the side effects of MMC during probing. Material and methods: It was a prospective, comparative, randomised interventional study. Patients were randomly divided into two groups of 20 each. Cases (20 eyes) with primary acquired NLD obstruction were treated with probing and intraoperative Mitomycin-C and controls (20 eyes) with primary acquired NLD obstruction were treated with only probing. At the end of 4 months, subjective improvement in epiphora and patency on syringing were evaluated. Results: On follow up at 4 months, 35% cases showed mild improvement compared to 25% of controls. Moderate improvement was seen in 10% of cases compared to 5% of controls. Complete improvement was seen in 15% of cases compared to 0% of controls. The overall subjective improvement was seen in 60% of cases compared to 30% of controls. On syringing, NLD was found patent in 15% of cases compared to 5% among controls at 4 months follow up. Conclusion: Our study confirmed the efficacy of probing with MMC in reducing the symptoms of epiphora with fewer side effects in patients with NLDO during 4 months of follow-up.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
